Bay Colony Advisors’s Novartis NVS Stock Holding History

Bay Colony Advisors’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-3,685	Closed	-$356K	–	443
2024 Q1	$356K	Buy	3,685 +377	+11%	+$38.7K	0.06%	262
2023 Q4	$334K	Buy	+3,308	New	+$319K	0.07%	262
2020 Q3	–	Sell	-4,673	Closed	-$408K	–	260
2020 Q2	$408K	Sell	4,673 -300	-6%	-$25.9K	0.29%	99
2020 Q1	$410K	Sell	4,973 -543	-10%	-$48.4K	0.37%	88
2019 Q4	$525K	Hold	5,516	–	–	0.34%	102
2019 Q3	$479K	Buy	5,516 +721	+15%	+$64.7K	0.33%	111
2019 Q2	$438K	Sell	4,795 -556	-10%	-$47.1K	0.28%	101
2019 Q1	$459K	Buy	5,351 +2,136	+66%	+$171K	0.3%	96
2018 Q4	$247K	Buy	+3,215	New	+$250K	0.21%	126
2018 Q3	–	Sell	-1,281	Closed	-$87K	–	668
2018 Q2	$87K	Buy	+1,281	New	+$88.4K	0.06%	273

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CCM

Cullen Capital Management New York $9.75B AUM 21.81% 1-Year Est. Return

Bay Colony Advisors's NVS Position: Q2 2024 in Review

Bay Colony Advisors sold out of Novartis (NVS) in Q2 2024, closing a stake of 3,685 shares — an estimated $356K sold.

Bay Colony Advisors first reported a position in NVS in Q2 2018 and held it in 10 quarters. The position peaked at $525K in Q4 2019. 1,306 funds tracked by Wall St. Rank hold NVS as of Q2 2024.

Bay Colony Advisors reported no remaining Novartis position as of Q2 2024 after selling out during the quarter.
Bay Colony Advisors sold 3,685 Novartis shares in Q2 2024, an estimated $356K.
Bay Colony Advisors first reported a position in Novartis in Q2 2018 and held it in 10 quarters.
Bay Colony Advisors's Novartis position peaked at $525K in Q4 2019.
1,306 funds tracked by Wall St. Rank held Novartis as of Q2 2024.

Based on Bay Colony Advisors's 13F filing for Q2 2024, filed 24 Jul 2024.